7.865

5.57% 0.415

Verastem Inc (VSTM)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Verastem Inc stock is traded at $7.865, with a volume of 28.81M. It is up +5.57% in the last 24 hours and up +4.73% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Previous Close:

$7.45

Open:

24h Volume:

28.81M

Relative Volume:

9.90

Market Cap:

$712.28M

Revenue:

$30.91M

Net Income/Loss:

$-209.47M

P/E Ratio:

-2.3634

EPS:

-3.3279

Net Cash Flow:

$-147.13M

1W Performance:

-4.84%

1M Performance:

+4.73%

6M Performance:

+28.09%

1Y Performance:

-12.61%

1-Day Range:

$6.70

$8.955

1-Week Range:

$7.445

$8.60

52-Week Range:

$3.43

$10.82

Verastem Inc Stock (VSTM) Company Profile

Name

Verastem Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(781) 292-4200

Address

117 KENDRICK STREET, NEEDHAM, MA

Employee

102

Twitter

@VerastemOncolog

Next Earnings Date

2026-11-03

Latest SEC Filings

VSTM's Discussions on Twitter

Compare VSTM vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VSTM Verastem Inc	7.865	712.28M	30.91M	-209.47M	-147.13M	-3.3279
VRTX Vertex Pharmaceuticals Inc	497.65	126.13B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	224.43	89.60B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	780.84	80.39B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	826.49	51.97B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	193.21	41.41B	742.00K	-1.37B	-1.07B	-7.0731

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-26	Initiated	Wolfe Research	Outperform
Mar-12-26	Resumed	BTIG Research	Buy
Feb-04-26	Initiated	H.C. Wainwright	Buy
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy
Mar-24-25	Reiterated	H.C. Wainwright	Buy
Dec-31-24	Reiterated	BTIG Research	Buy
Sep-30-24	Initiated	Guggenheim	Buy
Nov-21-23	Resumed	BTIG Research	Buy
Sep-27-23	Initiated	B. Riley Securities	Buy
Jun-15-23	Upgrade	Mizuho	Neutral → Buy
Sep-07-22	Resumed	Alliance Global Partners	Buy
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight
Apr-14-22	Initiated	RBC Capital Mkts	Outperform
Mar-09-22	Initiated	Truist	Buy
Jul-01-21	Initiated	Alliance Global Partners	Buy
May-24-21	Upgrade	BTIG Research	Neutral → Buy
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy
May-02-18	Initiated	Seaport Global Securities	Buy
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy
Sep-07-17	Reiterated	H.C. Wainwright	Buy
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy
Sep-29-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-28-15	Downgrade	Mizuho	Buy → Neutral
Sep-28-15	Downgrade	ROTH Capital	Buy → Neutral
Sep-09-15	Initiated	Raymond James	Strong Buy
May-12-15	Reiterated	UBS	Buy
Apr-08-15	Initiated	H.C. Wainwright	Buy
Jan-23-15	Reiterated	ROTH Capital	Buy
Jul-08-14	Resumed	Oppenheimer	Perform
Feb-11-14	Initiated	Mizuho	Buy

View All

Verastem Inc Stock (VSTM) Latest News

Oct 12, 2026

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? - Zacks Investment Research

Oct 12, 2026

Oct 08, 2026

Verastem's cancer drug sales hit $25.1M in Q2 '26; key trial data expected in October - Pluang

Oct 06, 2026

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM) - Seeking Alpha

Oct 06, 2026

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research

Oct 06, 2026

Oct 05, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Oct 05, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 05, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 05, 2026

VSTM Reiterates by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus

Oct 05, 2026

VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus

Oct 05, 2026

Oct 03, 2026

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 - BioSpace

Oct 03, 2026

Oct 02, 2026

To cover tax withholding, Verastem (VSTM) CEO sells 44,121 shares at $8 each. - Stock Titan

Oct 02, 2026

A 2,566-share sale at $8 covers vesting taxes for Verastem (VSTM) CFO Daniel Calkins. - Stock Titan

Oct 02, 2026

Oct 01, 2026

To cover vesting taxes, Dan Paterson plans to sell 44,121 shares of Verastem (VSTM). - Stock Titan

Oct 01, 2026

Sep 29, 2026

Preferred dividends of Verastem, Inc. – HAN:2VSA - TradingView

Sep 29, 2026

Discontinued operations of Verastem, Inc. – HAN:2VSA - TradingView

Sep 29, 2026

Verastem, Inc. Actuals & Estimates (HAN:2VSA) - TradingView

Sep 29, 2026

Verastem (NasdaqCM:VSTM) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 29, 2026

Sep 28, 2026

Verastem (VSTM) Shares React to Positive Two-Year Phase 2 RAMP 201 Study Results in Ovarian Cancer - GuruFocus

Sep 28, 2026

Half of patients with a specific ovarian cancer mutation stayed on treatment for over a year. - Stock Titan

Sep 28, 2026

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data By Investing.com - Investing.com Nigeria

Sep 28, 2026

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data - Investing.com

Sep 28, 2026

Sep 26, 2026

Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily

Sep 26, 2026

Sep 24, 2026

Verastem to present cancer treatment study data at IGCS meeting - Investing.com

Sep 24, 2026

Two ovarian cancer studies are selected for Montreal talks. One studied Japanese patients. - Stock Titan

Sep 24, 2026

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire

Sep 24, 2026

Sep 23, 2026

Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com

Sep 23, 2026

Form 4 Verastem Inc For: 23 September - Investing.com India

Sep 23, 2026

Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com Canada

Sep 23, 2026

Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus

Sep 23, 2026

After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan

Sep 23, 2026

Sep 21, 2026

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - Yahoo Finance

Sep 21, 2026

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView

Sep 21, 2026

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Sep 21, 2026

Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news

Sep 21, 2026

Sep 18, 2026

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com

Sep 18, 2026

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - Yahoo Finance

Sep 18, 2026